• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
 
Generic Name:  Double stranded oligomer ARO-APOC3 RNA interference-based liver targeted therapeutic
Trade Name:  N/A
Date Designated:  06/20/2019
Orphan Designation:  Treatment of Familial Chylomicronemia Syndrome
Orphan Designation Status:  Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date:  N/A
Approved Labeled Indication:  
Exclusivity End Date:    N/A
Arrowhead Pharmaceuticals, Inc.
225 South Lake Ave, Suite 1050
Pasadena, California 91101
USA

The sponsor address listed is the last reported by the sponsor to OOPD.
-
-